SV

Street Verdict

Analyst Scorecard

A record of what Vishal Manchanda said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on smaller CDMO (Contract Development and Manufacturing Organisation) companies, expecting them to deliver stronger returns as new contracts and growth opportunities emerge. This segment offers more potential compared to most large-cap pharma stocks, which are considered fairly valued after the pharma index's 18% gain.”
Nifty PharmaBullishCalled 01 Sep 2026
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Vishal Manchanda’s full track record